Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients

Nephrology

Volumn 19, Issue 11, 2014, Pages 672-678

  Lin, Hsin Hung ^a,c   Liou, Hung Hsiang ^e   Wu, Ming Shiou ^d   Lin, Ching Yuang ^b,c   Huang, Chiu Ching ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Hsin Jen Hospital   (Taiwan)

Author keywords

Chronic kidney disease; End stage renal disease; Fibroblast growth factor 23; Haemodialysis; Klotho; Sevelamer

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALCIUM; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; TRIACYLGLYCEROL; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; POLYAMINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; PHOSPHATE BLOOD LEVEL; PNEUMONIA; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SERUM FIBROBLAST GROWTH FACTOR 23; SERUM KLOTHO; STOMACH CANCER; UPPER ABDOMINAL PAIN; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TIME;

CALCIUM CARBONATE; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MALE; MIDDLE AGED; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 84907896361     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12319     Document Type: Article

References (30)

1. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 2004; 43: 572-9.
2. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008; 74: 148-57.
3. Bernheim J, Benchetrit S. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol. Dial. Transplant. 2011; 26: 2433-38.
4. John GB, Cheng CY, Kuro-o M. Role of Klotho in aging, phosphate metabolism, and CKD. Am. J. Kidney Dis. 2011; 58: 127-34.
5. Liu S, Quarles LD. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 2007; 18: 1637-47.
6. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600-8.
7. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 59: 584-92.
8. Nakatani T, Sarraj B, Ohnishi M et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J. 2009; 23: 433-41.
9. Pavik I, Jaeger P, Ebner L et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: A sequence suggested from a cross-sectional study. Nephrol. Dial. Transplant. 2013; 28: 352-9.
10. Yokoyama K, Imura A, Ohkido I et al. Serum soluble alpha klotho in hemodialysis patients. Clin. Nephrol. 2012; 77: 347-51.
11. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 2011; 22: 124-36.
12. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-52.
13. Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin. J. Am. Soc. Nephrol. 2010; 5: S31-40.
14. Nikolov IG, Joki N, Maizel J, Lacour B, Drüeke TB, Massy ZA. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int. 2006; 70: S16-23.
15. Brandenburg VM, Schlieper G, Heussen N et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study. Nephrol. Dial. Transplant. 2010; 25: 2672-9.
16. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther. Apher. Dial. 2005; 9: 336-9.
17. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 2010; 5: 286-91.
18. Yilmaz MI, Sonmez A, Saglam M et al. Vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am. J. Kidney Dis. 2012; 59: 177-85.
19. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J. Am. Soc. Nephrol. 2012; 23: 1407-15.
20. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast growth factor 23 in hemodialysis patients: Effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin. Pract. 2011; 117: c74-82.
21. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-78.
22. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. Soc. Nephrol. 2010; 21: 1427-35.
23. Smith ER, McMahon LP, Holt SG. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin. Chem. Lab. Med. 2013; 24: 1-11.
24. Lane NE, Parimi N, Corr M, Yao W et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The osteoporotic fractures in men (MrOS) study. J. Bone Miner. Res. 2013; 28: 2325-32.
25. Golembiewska E, Safranow K, Kabat-Koperska J, Mys̈lak M, Ciechanowski K. Serum soluble Klotho protein level is associated with residual diuresis in incident peritoneal dialysis patients. Acta Biochim. Pol. 2013; 60: 191-4.
26. Yasin A, Liu D, Chau L, Madrenas J, Filler G. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: A cross-sectional study. BMC Nephrol. 2013; 14: 39.
27. Heijboer AC, Blankenstein MA, Hoenderop J, de Borst MH. Vervloet MG on behalf of the NIGRAM consortium. Laboratory aspects of circulating á-Klotho. Nephrol. Dial. Transplant. 2013; 28: 2283-7.
28. Devaraj S, Syed B, Chien A, Jialal I. Validation of an immunoassay for soluble Klotho protein: Decreased levels in diabetes and increased levels in chronic kidney disease. Am. J. Clin. Pathol. 2012; 137: 479-85.
29. Semba RD, Cappola AR, Sun K et al. Plasma klotho and cardiovascular disease in adults. J. Am. Geriatr. Soc. 2011; 59: 1596-601.
30. Kitagawa M, Sugiyama H, Morinaga H et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS ONE 2013; 8: e56695.